🔬 #STAMPEDE2 is supported through collaboration with @NovartisSpain Scientific cooperation helps advance new treatment strategies for metastatic prostate cancer.  ----- 🔬#STAMPEDE2 cuenta con la colaboración de Novartis. La cooperación científica contribuye a avanzar nuevas estrategias terapéuticas en cáncer de próstata metastásico. #GUARDConsortium #Novartis #InvestigaciónClínica #GUARDConsortium #Novartis #ClinicalResearch @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🎓 Quedan 1 mes para solicitar las becas GUARD Consortium para cursar el Diploma de Especialización en Oncología Traslacional ASEICA–UCM 2027. Ofrecemos 2 becas del 100% para Faculty Members de GUARD. 📅 Deadline: 18 de octubre · 23:00 h 📝 Solicitud: form.jotform.com/26113184653… 📩 info@guardconsortium.org Consulta las bases: guardconsortium.org/wp-conte… #OncologíaTraslacional #FormaciónOncológica #GUARDConsortium #ASEICA @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

👤 Who can enter #STAMPEDE2? Men aged ≥18 with newly diagnosed or relapsed prostate cancer, starting long-term hormone therapy and with metastatic disease confirmed by conventional imaging and bone or PET imaging.   ------ 👤 ¿A quién va dirigido #STAMPEDE2?   Hombres ≥18 años con cáncer de próstata de novo o en recaída, que inician hormonoterapia prolongada y presentan enfermedad metastásica confirmada por imagen convencional y ósea o PET. #ProstateCancer #ClinicalTrial #EnsayoClínico #CáncerDePróstata #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🔬 GUARD Consortium presenta #NOVOPROST, estudio liderado por la Dra. Natalia Vidal y la Dra. M.ª José Juan @mjuanfi81 Analizará los patrones de tratamiento y las características clínicas y moleculares de pacientes con cáncer de próstata hormonosensible metastásico de novo en España. 📝 Faculty Members: participa antes del 12 OCT form.jotform.com/26250310423… #CáncerDePróstata #OncologíaGU #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🔬 Últimos días para optar a la Ayuda de Investigación GUARD Consortium en Tumores Genitourinarios. Una ayuda de 40.000 € destinada a impulsar proyectos independientes de investigación clínica y/o traslacional en cáncer de próstata, riñón, vejiga y otros tumores genitourinarios. Dirigida a profesionales de cualquier especialidad vinculada al abordaje de los tumores genitourinarios, con ejercicio profesional en España. 📅 Cierre de convocatoria: 27 de septiembre de 2026 📝 Inscripción: form.jotform.com/26113184653… 📄 Consulta las bases: guardconsortium.org/wp-conte… #InvestigaciónClínica #OncologíaTraslacional #OncologíaGU #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🎥 Así vivimos el #GUARDSymposium2026. Tres jornadas de conocimiento compartido, debate y colaboración para seguir avanzando en la investigación y el abordaje de los tumores genitourinarios. Gracias a todos los ponentes, asistentes, colaboradores y entidades que lo habéis hecho posible. Nos vemos en 2027. #GUARDConsortium #GUOncology #InvestigaciónClínica #TumoresGenitourinarios @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist

🔬 #STAMPEDE2 in numbers: • 3,360 patients • 180 planned in Spain • 18 participating sites in Spain • International collaboration across Spain, Germany and the UK A large-scale clinical trial advancing research in metastatic prostate cancer. ------ 🔬 #STAMPEDE2 en cifras: • 3.360 pacientes • 180 previstos en España • 18 centros participantes en España • Colaboración internacional entre España, Alemania y Reino Unido Un ensayo clínico de gran escala para avanzar en la investigación del cáncer de próstata metastásico. #EnsayoClínico #CáncerDePróstata #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

My thoughts on biomarkers at #GUARDSimpossium26 👇🏼 1) ADCs change the way we think of biomarkers. – HER2 acts as a delivery address and is rarely expressed in isolation. – Integrating amplification and membranous nectin4 has shown correlation with EV responses. @Oncoalert

4) IM011 makes ctDNA clinically actionable in the adjuvant space. And ctDNA can also be measured as a continuous variable, not just a binary positive/negative. Similarly to PSA: burden, timing and kinetics matter. @OncoAlert @GuardConsortium @tompowles1

✍️ what about the future in the management of advanced MIBC. A superstar @DrRosenbergMSK showing the cristal ball! 💯 @OncoAlert @apolo_andrea @PGrivasMDPhD @tompowles1 @aaoncoclinica

🚨 DAY 3 | #GUARDSymposium2026 🇪🇸 🌌 When does “advanced” urothelial cancer really begin? 🎙️ Dr. @tompowles1 🇬🇧 | Barts Cancer Institute 📡 @OncoAlert × @GuardConsortium A fascinating way to start the advanced bladder cancer session. Powles used Andromeda to challenge a very simple assumption: What we can see is not necessarily all the disease that is already there. Radiology defines visible disease. But micrometastatic disease may already exist below the threshold of imaging — and ctDNA may allow us to detect that biology earlier. This raises a provocative question: 👉 Does “advanced disease” begin when metastases become radiologically visible — or when molecular evidence tells us the disease has already escaped? Post-surgery ctDNA levels clearly stratify prognosis, and dynamic changes can be informative very early: 🔹 clearance → better outcomes 🔹 falling ctDNA → intermediate risk 🔹 persistent or rising ctDNA → substantially worse prognosis So perhaps the boundary between localized and advanced disease is becoming less anatomical and more biological. And then came the historical perspective. A few years ago, first-line trials were still asking whether adding checkpoint inhibition to platinum chemotherapy could meaningfully move the needle. Now, EV-302/KEYNOTE-A39 has completely changed the first-line landscape. At ~3.5 years of follow-up, EV + pembrolizumab continues to show durable benefit, but one detail is particularly striking: complete responses can deepen over time. Among patients achieving CR with EV + pembrolizumab, many did not start with CR. They first achieved a partial response — and then converted to CR later. And importantly, patients whose response deepened from PR → CR had similar 3.5-year survival to the overall CR population: 82.4% vs 83.6%. That changes how we think about response assessment. 🎯 My takeaway: We may need to rethink two traditional boundaries in urothelial cancer: 1️⃣ When does advanced disease really begin? Perhaps before radiology can see it. 2️⃣ When is the final depth of response really known? Perhaps much later than the first scan suggests. From ctDNA-detected molecular disease to delayed conversion from PR to CR, the common theme is the same: biology evolves continuously — our clinical categories are the ones that are discrete. And that may be one of the most important lessons as treatment becomes more effective. @OncoAlert @GuardConsortium @cdanicas @tompowles1 @DrRosenbergMSK @AndreaNecchi @urbano_anido @drenriquegrande @mjuanfi81 @tonivilaseca @MarioHArroyo @DrJaVallejo @dralvaropinto @Ecastromarcos @OncBrothers #BladderCancer #UrothelialCancer #ctDNA #GUOncology

🟠 DIRECTO #GUARDSymposium2026 El Dr. Daniel Castellano @cdanicas clausura tres días de conocimiento compartido, debate y colaboración para seguir avanzando en el abordaje de los tumores genitourinarios. Gracias a todos los que lo habéis hecho posible. ¡Nos vemos en 2027! #UroOncología #InvestigaciónClínica #GUARDConsortium @DrFelixGuerrero @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @F_lopez_campos @MarioHArroyo

🟠 DIRECTO #GUARDSymposium2026  Última ponencia a cargo del Dr. Jonathan E. Rosenberg @DrRosenbergMSK donde aborda el futuro de los ADC y los biomarcadores en cáncer de vejiga avanzado: más alternativas terapéuticas y mayor precisión en la selección de pacientes. @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @F_lopez_campos @MarioHArroyo

🟠 DIRECTO #GUARDSymposium2026  El Dr. Urbano Anido @urbano_anido revisa la secuenciación terapéutica en cáncer de vejiga avanzado tras EV + pembrolizumab en primera línea. El platino continúa siendo el estándar en segunda línea en práctica clínica real. La elección entre cisplatino y carboplatino debe adecuarse al estado del paciente. La determinación precoz de FGFR3 y HER2 será clave para orientar las opciones posteriores y avanzar hacia una secuenciación basada en biomarcadores. @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @F_lopez_campos @MarioHArroyo

🟠 DIRECTO #GUARDSymposium2026 con el Dr. Urbano Anido @urbano_anido

🚨 DAY 3 #GUARDSymposium2026 🇪🇸 PART 3 🟣 Who gets EV + pembrolizumab today — and who might get it tomorrow? 🎙️ @tompowles1 🇬🇧 | Barts Cancer Institute 📡 @OncoAlert × @GuardConsortium Perhaps the most provocative part of the discussion was what comes after establishing EV + pembrolizumab as a highly active first-line strategy. The next questions are no longer only about efficacy. They are about duration, de-escalation, biomarkers and moving treatment into earlier disease. Real patients illustrate why this is difficult: 🔹 prolonged benefit can coexist with cumulative symptomatic toxicity 🔹 treatment may need to be interrupted or one component discontinued 🔹 ctDNA can change before conventional clinical progression 🔹 even patients achieving pCR and ctDNA clearance may ultimately relapse So how should we use all that information? 👉 Can ctDNA help determine when treatment can safely stop? 👉 Can it identify molecular relapse before imaging? 👉 When toxicity forces EV discontinuation, should pembrolizumab continue? 👉 Can EV + P be successfully reintroduced? 👉 And should ADC–ICI combinations move into MIBC and bladder-preservation strategies? Trials exploring approaches such as sac-TMT + pembrolizumab with trimodality therapy are already pushing this concept into earlier-stage disease. And that creates an important shift: The same drugs that transformed metastatic disease may eventually force us to rethink treatment goals in localized disease. 🎯 My takeaway: the future of ADC + immunotherapy in urothelial cancer may be less about adding more treatment and more about learning who needs what, for how long, and at which disease stage. The hardest question may no longer be: “Does EV + pembrolizumab work?” but rather: “How do we personalize its use once it works?” @OncoAlert @GuardConsortium @cdanicas @tompowles1 @DrRosenbergMSK @AndreaNecchi @urbano_anido @mjuanfi81 @drenriquegrande @tonivilaseca @MarioHArroyo @DrJaVallejo @dralvaropinto @Ecastromarcos @OncBrothers #BladderCancer #UrothelialCancer #ctDNA #GUOncology

🟠 DIRECTO #GUARDSymposium2026  “Los rápidos cambios en cáncer de vejiga están logrando mejores resultados para los pacientes.” El Dr. Thomas Powles @tompowles1 analiza las nuevas perspectivas en primera línea de cáncer de vejiga avanzado y los cambios que ya están mejorando los resultados de los pacientes. #CáncerDeVejiga #BladderCancer #Oncología #InvestigaciónClínica #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @F_lopez_campos @MarioHArroyo

🚨 DAY 2/| #GUARDSymposium2026 🇪🇸 Coverage by OncoAlert Adjuvant pembrolizumab is now standard of care in high-risk RCC—so how do we build on it, and who should get belzutifan on top? 🎗️ At #GUARDSymposium2026, Dr. Roberto Iacovelli 🇮🇹, Servicio de Oncología Médica, Policlinico Universitario Agostino Gemelli, Roma, reviews the current status of adjuvant therapy in high-risk clear-cell #RCC, from early trials that failed to improve OS to pembrolizumab's DFS and OS benefit, and the added DFS gain with belzutifan—while OS data are still maturing and the risk-benefit profile is weighed case by case. #KidneyCancer @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campo @DrIacovelli @tompowles1 @mjuanfi81 @AndreaNecchi @Martin_AngelMD @cinthiavgauna @NicosiaMd @GiuliaMarvaso84 @ArkaitzLab @Dolmos77 @alvarojuarezs @Prof_Nick_James @Dav_Lorente @charlesryanmd @Uro_Dominguez @JaviMolinaC @g_develasco @tonivilaseca @MarioHArroyo @urbano_anido @DrRosenbergMSK @GuardConsortium

✨️ DAY 3 #GUARDSymposium2026 🇪🇸 One of the most clinically relevant questions in localized #BladderCancer right now: Are we finally ready to use ctDNA not just to predict relapse, but to guide what we do next? Dr. Sara Coca Membribes 🇬🇧 reviewed the biomarker landscape shaping therapy in urothelial cancer: 🧬 DNA alterations 🎯 FGFR3 🔬 ADC targets such as HER2 and Nectin-4 🛡️ PD-L1 and immune signatures But for me, the most important story is ctDNA. Data from IMvigor010/011 and NIAGARA reinforce that ctDNA can: 🔹 identify molecular residual disease 🔹 anticipate relapse before it becomes radiographically visible 🔹 refine postoperative risk 🔹 potentially help select patients for adjuvant escalation 🔹 and, perhaps just as importantly, spare some patients unnecessary treatment The next step is even more exciting: combining ctDNA + utDNA to support response-adapted bladder-preservation strategies. 🎯 My takeaway: precision oncology becomes truly meaningful when a biomarker changes a decision. The tumor does not need to relapse visibly first. Sometimes the molecular signal comes months earlier — and the challenge is knowing when we are ready to act on it. @Uro_Oncologist @RodriguezFaba @DrFelixGuerrero @cdanicas @drenriquegrande @DrJaVallejo @Maroto5Pablo @AnaPlatabello1 @AndreaNecchi @GuardConsortium #ctDNA #MRD #UrothelialCancer #PrecisionOncology #GUOncology

🚨 DAY 3 #GUARDSymposium2026 🇪🇸 PART 2 🟣 EV + pembrolizumab: responses can deepen with time — and toxicity management matters 🎙️ Dr. Urbano Anido 🇪🇸 📡 @OncoAlert × @GuardConsortium This second part of the case highlighted something increasingly relevant in advanced #UrothelialCancer: an early partial response may not be the final depth of response. With longer follow-up from EV-302/KEYNOTE-A39: 🔹 ORR 67.5% with EV + pembrolizumab 🔹 CR 30.4% vs 14.5% with chemotherapy 🔹 Among patients achieving CR with EV + P, ~2/3 initially had a partial response before converting to CR 🔹 Median time to CR was 4.3 months overall and 6.6 months among those converting from PR to CR And durability remains striking: ➡️ median OS 33.6 vs 15.9 months ➡️ HR 0.53 ➡️ 44% alive at 3.5 years vs 24.6% with chemotherapy But longer treatment also means a different clinical challenge: how do we preserve benefit without allowing cumulative toxicity to compromise the patient? In the presented case, EV dose was reduced after emerging neuropathy, while treatment continued. The longer-term safety data are reassuring in one respect: prolonged exposure did not appear to produce a major increase in grade ≥3 toxicity overall. However, peripheral sensory neuropathy remains the toxicity that increasingly matters with time, making dose interruption and reduction part of treatment optimization, not necessarily treatment failure. 🎯 My takeaway: with EV + pembrolizumab, we may need to think differently about response kinetics. A patient with an early PR may still deepen the response months later, while careful dose modification can help preserve treatment exposure. The challenge is therefore not only to achieve response — but to sustain it long enough, and safely enough, for its full depth to emerge. And one caveat: long-duration treatment analyses are inherently enriched for patients who were benefiting and tolerating therapy, so they should not be interpreted as randomized comparisons of treatment duration. @OncoAlert @GuardConsortium @cdanicas @urbano_anido @tompowles1 @AndreaNecchi @DrRosenbergMSK @mjuanfi81 @drenriquegrande @tonivilaseca @MarioHArroyo @DrJaVallejo @dralvaropinto @Ecastromarcos @OncBrothers #BladderCancer #UrothelialCancer #GUOncology